Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week randomized double-blind placebo-controlled trial of SNMC in chronic hepatitis C non-responders
2004-000773-60Phase 3Completed
- Sponsor
- Healthcare & Pharma Consulting
- Start
- Jan 2005
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of glycyrrhizin in hepatitis C virus infection (3 arms), sponsored by Healthcare & Pharma Consulting. Primary endpoints: Improvement in HAI score after 52 weeks of treatment and Proportion of patients with at least 50% ALT reduction within the 12-week double-blind treatment phase. Started Jan 2005; status: completed.
02
Drugs
glycyrrhizin
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2004-000773-60.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000773-60.